Key result
Genetic myocardial inhibition of CaMKII significantly decreased cardiac fatty acid uptake and oxidation, and reduced cardiac hypertrophy and apoptosis 2 weeks post-myocardial infarction.
Why the study?
CaMKII is triggered by myocardial ischemia, but its function in fatty acid metabolism remains unclear.
Does genetic myocardial inhibition of CaMKII reduce myocardial fatty acid uptake and oxidation after myocardial infarction in preclinical models?
Does genetic myocardial inhibition of CaMKII reduce myocardial fatty acid uptake and oxidation after myocardial infarction in preclinical models?
CaMKII inhibition represses fatty acid metabolism by interacting with AMPK signaling pathways, which reduces cardiac hypertrophy and apoptosis post-myocardial infarction.
/calmodulin-dependent protein kinase II (CaMKII) is also triggered by myocardial ischemia, but its function in FA metabolism remains unclear. Here, we explored the role of CaMKII in FA metabolism during myocardial ischemia by investigating the effects of cardiac CaMKII on AMPK-acetyl-CoA carboxylase (ACC), malonyl CoA decarboxylase (MCD), and FA translocase cluster of differentiation 36 (FAT/CD36), as well as cardiac FA uptake and oxidation. Moreover, we tested whether CaMKII and AMPK are binding partners. We demonstrated that diseased hearts from patients with terminal ischemic heart disease displayed increased phosphorylation of CaMKII, AMPK, and ACC and increased expression of MCD and FAT/CD36. AC3-I mice, which have a genetic myocardial inhibition of CaMKII, had reduced gene expression of cardiac AMPK. In post-MI (myocardial infarction) AC3-I hearts, AMPK-ACC phosphorylation, MCD and FAT/CD36 levels, cardiac FA uptake, and FA oxidation were significantly decreased. Notably, we demonstrated that CaMKII interacted with AMPK α1 and α2 subunits in the heart. Additionally, AC3-I mice displayed significantly less cardiac hypertrophy and apoptosis 2 weeks post-MI. Overall, these findings reveal a unique role for CaMKII inhibition in repressing FA metabolism by interacting with AMPK signaling pathways, which may represent a novel mechanism in ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Meng et al. (2022) studied Ischemic heart disease. Genetic myocardial inhibition of CaMKII was evaluated on Cardiac fatty acid uptake and oxidation. Genetic myocardial inhibition of CaMKII significantly decreased cardiac fatty acid uptake and oxidation, and reduced cardiac hypertrophy and apoptosis 2 weeks post-myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: